Newland Pharmaceutical Co., Ltd. (SHE:301277)
China flag China · Delayed Price · Currency is CNY
11.80
-0.33 (-2.72%)
At close: Mar 20, 2026

Newland Pharmaceutical Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
4,7564,6233,8734,1633,850-
Market Cap Growth
16.88%19.35%-6.96%8.12%--
Enterprise Value
4,0463,9133,0723,3783,952-
Last Close Price
12.1311.799.6410.199.28-
PE Ratio
39.1338.1322.3126.1929.10-
PS Ratio
7.076.885.336.396.14-
PB Ratio
3.072.982.512.872.83-
P/TBV Ratio
3.173.082.572.952.92-
P/FCF Ratio
305.81297.23242.5025.55452.81-
P/OCF Ratio
40.6739.5330.5616.0446.47-
EV/Sales Ratio
6.025.824.235.196.30-
EV/EBITDA Ratio
21.6021.0014.2217.7223.61-
EV/EBIT Ratio
30.3429.3416.9820.8727.20-
EV/FCF Ratio
260.19251.61192.3320.73464.84-
Debt / Equity Ratio
0.000.000.000.000.000.31
Debt / EBITDA Ratio
0.030.030.010.010.030.80
Debt / FCF Ratio
0.370.370.190.020.675.34
Net Debt / Equity Ratio
-0.46-0.46-0.52-0.59-0.550.21
Net Debt / EBITDA Ratio
-3.82-3.82-3.72-4.49-4.460.53
Net Debt / FCF Ratio
-45.84-45.84-50.32-5.26-87.833.53
Asset Turnover
0.370.370.420.410.570.86
Inventory Turnover
7.457.4511.509.306.124.81
Quick Ratio
5.815.815.267.897.141.42
Current Ratio
6.266.265.518.297.611.82
Return on Equity (ROE)
7.76%7.76%11.56%11.19%14.92%31.91%
Return on Assets (ROA)
4.64%4.64%6.61%6.44%8.25%14.32%
Return on Invested Capital (ROIC)
14.46%15.14%23.81%23.31%24.30%27.06%
Return on Capital Employed (ROCE)
8.30%8.30%11.30%11.00%10.50%30.50%
Earnings Yield
2.55%2.62%4.48%3.82%3.44%-
FCF Yield
0.33%0.34%0.41%3.91%0.22%-
Dividend Yield
2.28%-2.96%2.00%1.83%-
Payout Ratio
92.39%92.39%46.08%41.94%5.12%31.92%
Buyback Yield / Dilution
0.88%0.23%-0.39%-29.52%-2.59%-0.64%
Total Shareholder Return
3.17%0.23%2.57%-27.51%-0.75%-0.64%
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.